A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever

NCT06006559

Status	RECRUITING
Phase	Phase 2
Sponsor	Novartis Pharmaceuticals
Enrollment	108 participants

Key Eligibility Criteria

Inclusion (6)

- Male or female, 18 - 60 years old (inclusive).
- History or presence of fever (e 38°C). At least one of the following criteria indicating dengue infection:
- Nausea or vomiting.
- Presence of rash, aches or pains including headache, muscle or joint pain.
- Onset of fever d 48 hours prior to treatment start.

... and 1 more (see full listing online)

Exclusion (19)

- Participants with any of abnormalities of clinical laboratory parameters.
- Usage of any anticoagulant drugs.
- Current significant medical conditions or illness that the investigator considers should exclude the participants, especially those that require continuation of other medications likely to have an interaction with the study drug.
- Pregnant or nursing (lactating) women.
- Clinical signs and symptoms for severe dengue according to Dengue Guideline (WHO 2009) at screening.

... and 14 more (see full listing online)

Locations (23 total)

Novartis Investigative Site, Manaus, Amazonas, Brazil
Novartis Investigative Site, Brasília, Federal District, Brazil
Novartis Investigative Site, Rio de Janeiro, Rio de Janeiro, Brazil
... and 20 more locations